Methodological advances in the discovery of novel neuroblastoma therapeutics. (1st February 2022)

• Record Type: Journal Article
• Authors: Segura, Miguel F.; Soriano, Aroa; Roma, Josep; Piskareva, Olga; Jiménez, Carlos; Boloix, Ariadna; Fletcher, Jamie I.; Haber, Michelle; Gray, Juliet C.; Cerdá-Alberich, Leonor; Martínez de Las Heras, Blanca; Cañete, Adela; Gallego, Soledad; Moreno, Lucas
• Is Part Of: Expert opinion on drug discovery. Volume 17:Number 2(2022)
• Page Start: 167
• Page End: 179
• Publication Date: 2022-02-01
• Subjects: Functional genomics -- genetically engineered murine models -- immunotherapy -- liquid biopsy -- neuroblastoma -- next generation sequencing -- patient-derived xenografts -- radiogenomics -- 3D in vitro models; 615.1
• DOI: 10.1080/17460441.2022.2002297
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction: Neuroblastoma is a cancer of the sympathetic nervous system that causes up to 15% of cancer-related deaths among children. Among the ~1, 000 newly diagnosed cases per year in Europe, more than half are classified as high-risk, with a 5-year survival rate <50%. Current multimodal treatments have improved survival among these patients, but relapsed and refractory tumors remain a major therapeutic challenge. A number of new methodologies are paving the way for the development of more effective and safer therapies to ultimately improve outcomes for high-risk patients. Areas covered: The authors provide a critical review on methodological advances aimed at providing new therapeutic opportunities for neuroblastoma patients, including preclinical models of human disease, generation of omics data to discover new therapeutic targets, and artificial intelligence-based technologies to implement personalized treatments. Expert opinion: While survival of childhood cancer has improved over the past decades, progress has been uneven. Still, survival is dismal for some cancers, including high-risk neuroblastoma. Embracing new technologies (e.g. molecular profiling of tumors, 3D in vitro models, etc.), international collaborative efforts and the incorporation of new therapies (e.g. RNA-based therapies, epigenetic therapies, immunotherapy) will ultimately lead to more effective and safer therapies for these subgroups of neuroblastoma patients.